In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Watson gets US rights to Columbia's progesterone assets; agreement later ends

Executive Summary

Just days after gaining rights to the Population Council's contraceptive vaginal ring, Watson Pharmaceuticals Inc. has signed another deal in women's health, gaining exclusive US rights to Columbia Laboratories Inc.'s (drug delivery technologies) progesterone assets. Included in the $47mm up-front payment is the purchase of 11.2mm common shares at the current market price.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies